The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...

Ampersand Biosciences and Trudeau Institute have been awarded more than $1 million to study infectious diseases.

BOSTON, Oct. 31, 2024 /PRNewswire/ -- For the third consecutive year, Ampersand Capital Partners has been named to Inc.'s 2024 Founder-Friendly Investors list, which honors the private equity and ...

Ampersand Advocates has announced the launch of an innovative digital engagement channel specifically designed for Personal ...

One item that particularly piqued Anolik’s interest was an unsent letter to Joan Didion from 1972, chastising her for, among other things, not reading Virginia Woolf. The allure of greater ...

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector.